Ubrelvy vs Qulipta
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Ubrelvy | US Qulipta | |
|---|---|---|
| Generic name | ubrogepant | atogepant |
| Drug class | CGRP Receptor Antagonist | CGRP Receptor Antagonist |
| Treats | Acute migraine | Migraine prevention |
| Category | Neurology | Neurology |
| Manufacturer | AbbVie | AbbVie |
| Year approved | 2019 | 2021 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $160M | $120M |
| Common side effects | Nausea, Drowsiness, Dry mouth | Nausea, Constipation, Fatigue, Decreased appetite |
Frequently asked questions
Is Ubrelvy or Qulipta better?
Neither is universally "better." Ubrelvy (ubrogepant) and Qulipta (atogepant) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Ubrelvy and Qulipta?
Ubrelvy is a CGRP Receptor Antagonist made by AbbVie, while Qulipta is a CGRP Receptor Antagonist made by AbbVie. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Ubrelvy has the larger estimated TV advertising budget of the two.